Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in USD (TTM)52.79bn
  • Net income in USD22.98bn
  • Incorporated1996
  • Employees108.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:SWX since
Gyroscope Therapeutics Holdings PLC(WAS 4L1215)Deal completed22 Dec 202122 Dec 2021Deal completed4.91%1.50bn
Alnylam Pharmaceuticals IncRumoured18 Nov 202118 Nov 2021Rumoured9.24%--
Arctos Medical AGDeal completed21 Sep 202121 Sep 2021Deal completed7.84%--
Data delayed at least 15 minutes, as of Aug 09 2022 16:36 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Takeda Pharmaceutical Co Ltd26.60bn1.46bn45.85bn47.35k31.050.96077.781.72126.39126.392,296.994,085.660.26881.364.5275,862,610.001.481.861.732.2467.7568.855.506.980.74853.530.4215123.9411.6115.56-38.8114.8910.680.00
Chugai Pharmaceutical Co Ltd8.93bn2.88bn46.44bn7.66k15.794.70--5.20236.46236.46732.88794.740.83111.964.71157,319,400.0026.8216.0732.4019.4166.0861.1732.2623.473.08--0.0044.3827.0415.2541.1041.4114.8834.40
Bayer AG49.31bn4.32bn53.04bn101.91k12.271.376.191.084.314.3149.2238.700.3981.713.47485,331.803.51-1.374.71-1.7761.8959.998.82-3.730.83765.450.5388--6.484.76106.42-23.200.2547-5.52
Novartis AG (ADR)52.79bn22.98bn205.78bn108.00k8.422.987.093.9010.2110.2123.5728.830.42762.196.19506,005.4018.619.0824.2511.5670.9270.6243.5324.731.13--0.3358.805.971.38197.5829.050.63113.31
Roche Holding AG67.41bn15.35bn275.91bn100.92k17.8610.0413.214.0917.6817.6877.2031.460.73742.395.73637,960.8018.1915.6227.7023.7769.1871.0424.6621.820.803720.320.489562.047.684.42-2.557.78-1.992.55
Data as of Aug 09 2022. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD

Institutional shareholders

4.28%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Mar 202227.84m1.16%
PRIMECAP Management Co.as of 31 Mar 202217.78m0.74%
Loomis, Sayles & Co. LPas of 30 Jun 202215.49m0.64%
Fisher Asset Management LLCas of 31 Mar 202210.87m0.45%
Franklin Mutual Advisers LLCas of 31 Mar 20227.14m0.30%
Managed Account Advisors LLCas of 31 Mar 20226.27m0.26%
Boston Partners Global Investors, Inc.as of 31 Mar 20224.61m0.19%
Charles Schwab Investment Management, Inc.as of 31 Mar 20224.40m0.18%
Dimensional Fund Advisors LPas of 31 Mar 20224.36m0.18%
Wellington Management Co. LLPas of 31 Mar 20224.13m0.17%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.